<DOC>
	<DOCNO>NCT00299208</DOCNO>
	<brief_summary>The goal study develop safe , well tolerate , highly efficacious azithromycin combination treatment uncomplicated falciparum malaria . Azithromycin drug show potential malaria treatment . It combine malaria drug currently approve treatment Thailand . About 120 people , age 20-65 , enrolled Thailand . Participants severe case malaria hospitalize 28 day treatment .</brief_summary>
	<brief_title>Azithromycin Combination Therapy Malaria</brief_title>
	<detailed_description>The study aim identify well tolerate , practical highly efficacious treatment regimen azithromycin combination artesunate quinine uncomplicated falciparum malaria future study , monitor tolerability safety combination regimen compare tolerability , safety efficacy azithromycin give combination artesunate compare quinine . This study also aim compare tolerability , safety efficacy combination artesunate azithromycin give single daily dose ( 200mg As+1000mg Az ) 3 day compare 2 dos 100mg As+750mg Az per day 3 day compare tolerability , safety efficacy combination quinine azithromycin give 3 daily dos quinine ( 10mg/kg ) + Az 500mg vs. 2 daily dos quinine ( 10mg/kg ) + Az 750mg give 3 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>1 . Acute symptomatic falciparum malaria infection determine malaria smear parasite density 100 100,000 asexual parasites/µL fever , define &gt; 37.5ºC , current illness , history ( within last 48 hour ) fever . 2 . Age : 2065 year old 3 . Male female . All female require negative human chorionic gonadotropic ( hCG ) pregnancy test ( urine ) . All female childbearing potential ( surgically sterile , less two year post menopausal ) require use acceptable method contraception , implant , injectable , oral contraceptive ( ) additional barrier contraception , intrauterine device , sexual abstinence , vasectomized partner , throughout study . 4 . Written inform consent obtain . 5 . Willing stay hospitalize 28 day treatment observation . 6 . Otherwise healthy outpatient ( clinicallysignificant illness describe Exclusion Criteria , # 6 ) . 1 . Pregnant woman , nurse mother , woman childbearing potential use acceptable method contraception ( describe Inclusion Criteria , # 3 ) . 2 . Mixed malaria infection admission malaria smear . 3 . A previous state intolerance hypersensitivity study drug quinine , artesunate , azithromycin drug similar chemical structure ( quinidine , artemisinin derivative , macrolides erythromycin ) . 4 . Malaria drug therapy administer past 30 day history ( quinine , chloroquine , mefloquine , artemisinin derivative , sulfadoxine/pyrimethamine , lumefantrine ) . 5 . Previous participation trial , participation study involve investigational market product , concomitantly within 30 day prior entry study . 6 . Clinically significant illness ( intercurrent illness e.g . pneumonia , preexist condition e..g. malignancy condition may effect absorption study medication e.g . severe diarrhea sign malnutrition define clinically ) . 7 . Laboratory evidence history significant cardiovascular , liver renal functional abnormality , opinion investigator would place increase risk . Specifically , follow serve exclusionary laboratory value : 1 . Creatinine &gt; 1.4 X ULN ( &gt; 2.0 mg/dl ) , 2 . Glucose &lt; LLN ( 75 mg/dl ) , 3 . AST , ALT &gt; 3x ULN ( 120 U/L ) , 4 . Prolonged QT wave baseline electrocardiogram ( QT &gt; 0.45s ) 8 . Symptoms severe vomit ( food inability take food previous 8 hour ) . 9 . Signs symptom severe malaria . 10 . Anyone receive transfusion red blood cell within prior 30 day . 11 . Unable and/or unlikely comprehend and/or follow protocol . 12 . Selfreported alcohol and/or drug abuse . 13 . Likelihood require treatment study period drug permit study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Malaria</keyword>
</DOC>